|Court:||United States District Court for the District of New Jersey|
|Class Period:||10/29/2013 - 11/02/2016|
|Case Leaders:||John C. Browne, Lauren A. Ormsbee|
|Case Team:||Michael Mathai, Nicholas Gersh, Erika Connolly|
This case asserts claims against Allergan plc (formerly doing business as Actavis) (“Allergan”) and its top executives for violation of Sections 10(b) and 14(a) of the Securities Exchange Act of 1934. This securities class action is asserted on behalf of investors who purchased the publicly-traded securities of Allergan from October 29, 2013 through November 2, 2016 (the “Class Period”). Specifically, Plaintiffs allege that Defendants reported robust financial results to the market, attributed those results to entirely legitimate business factors and conditions, and assured investors that both the Company’s pricing practices and the generic drug market in which it operated were highly competitive. The Complaint alleges that, in truth, Allergan’s financial results were driven in material part by the Company’s collusion with competitors to dramatically increase the prices of at least six generic drugs. The Complaint further alleges that the truth about Allergan’s price fixing scheme was revealed to investors in two disclosures on August 6, 2015 and November 3, 2016.
On February 2, 2017, the Court appointed Union Asset Management as co-Lead Plaintiff for the action. On May 1, 2017, Lead Plaintiffs filed an initial Amended Complaint. Defendants moved to dismiss that complaint. That motion was fully briefed when, on October 31, 2017, a consortium of 46 state Attorneys General filed a complaint charging Allergan as an alleged co-conspirator in an antitrust price-fixing conspiracy. This complaint described several “smoking gun” calls, emails and text between Allergan executives and other co-conspirators. On November 28, 2017, Lead Plaintiffs filed a Second Amended Complaint, which included newly-discovered information, including information revealed in the Attorneys General’s complaint.
Defendants filed a renewed motion to dismiss on January 22, 2018. The motion was fully briefed in April 2018, and was argued on April 11, 2019. A decision is pending.
On August 6, 2019, the Court denied Defendants’ motion to dismiss, and the case is now in discovery. Plaintiffs’ motion for class certification was filed March 20, 2020, and was fully briefed on January 14, 2020. Fact discovery closed on March 31, 2021, and the deadline for expert discovery is October 29, 2021.
- Events BLB&G Hosts Annual 2021 Institutional Shareholder Conference in Amsterdam September 9, 2021 Learn More
- Publications "Forensic Linguistics and the Telephone Interview" by Jenna Goldin published by The New York City Fraud Examiner July 21, 2021 Learn More
- Awards Benchmark Litigation Names Six BLB&G Partners to Its “40 & Under Hot List” July 21, 2021 Learn More
- Events BLB&G Partner David Wales Speaks at the Practising Law Institute's webinar "ESG 2021: What It Means for Boards, Management, and Counsel" June 24, 2021 Learn More
- Publications "Important Considerations in Deciding Whether to Opt Out of Securities Class Actions" by Jonathan Uslaner published in Reuters June 23, 2021 Learn More